ReviewJournal of inflammation research2025
Research Progress on Th17/Treg Cell Imbalance in Epileptic Seizures.
Review in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Innate immune signalling, neuroinflammation and network plasticity in temporal lobe epilepsy.Frontiers in pharmacology · 2026Review
- The spatial architecture of neuroimmune interactions in epilepsy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is associated with widespread neurological circumstances due to aberrant neuronal discharges in the brain, which have significant adverse effects on patient's quality of life and increase their risk of death. Immune imbalance, particularly disruption of the Th17/Treg cell balance, has gained increasing attention in the pathophysiology of epilepsy as our understanding of neuroimmune interactions improves. This paper examines the potential therapeutic effects and thoroughly discusses the processes by which the Th17/Treg cell imbalance contributes to the development of epilepsy. The primary emphasis is on the mechanism by which this imbalance impairs blood-brain barrier integrity, neuroinflammation, and other elements. On the therapeutic front, targeting the Th17/Treg axis for immune regulation-through approaches such as ketogenic diets, nanomaterials, and gene editing-shows promising prospects for restoring immune balance. By furthering our knowledge of the connection between Th17/Treg cell imbalance and epilepsy etiology, this work offers a crucial theoretical foundation for creating innovative immunotherapy approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.